{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:30:44Z","timestamp":1790195444473,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01052"],"award-info":[{"award-number":["PI20\/01052"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jcyt.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T07:37:53Z","timestamp":1700725073000},"page":"113-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5497-1724","authenticated-orcid":false,"given":"Siyuan","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Jim\u00e9nez-Galanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9347","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Guadalajara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-1373","authenticated-orcid":false,"given":"Mariano","family":"Garc\u00eda-Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dami\u00e1n","family":"Garc\u00eda-Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-5593","authenticated-orcid":false,"given":"Pedro","family":"Villarejo-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcyt.2023.10.007_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.jcyt.2023.10.007_bib0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr Probl Surg"},{"issue":"12","key":"10.1016\/j.jcyt.2023.10.007_bib0003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/DCR.0b013e3182a62d9d","article-title":"Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin","volume":"56","author":"Thomassen","year":"2013","journal-title":"Dis Colon Rectum"},{"issue":"27","key":"10.1016\/j.jcyt.2023.10.007_bib0004","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: optimal management review","volume":"25","author":"Rodr\u00edguez-Ortiz","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.10.007_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","article-title":"Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies","volume":"243","author":"Koppe","year":"2006","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"issue":"12","key":"10.1016\/j.jcyt.2023.10.007_bib0007","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal carcinomatosis from colorectal cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br J Surg"},{"issue":"20","key":"10.1016\/j.jcyt.2023.10.007_bib0008","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2023.10.007_bib0009","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.soc.2018.02.011","article-title":"Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives","volume":"27","author":"Go\u00e9r\u00e9","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2023.10.007_bib0011","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement","volume":"14","author":"Esquivel","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0012","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/jso.25438","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer","volume":"119","author":"Eng","year":"2019","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.10.007_bib0013","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.jcyt.2023.10.007_bib0014","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"9967","key":"10.1016\/j.jcyt.2023.10.007_bib0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jcyt.2023.10.007_bib0016","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2040620715588916","article-title":"CD19-redirected chimeric antigen receptor-modified T cells: A promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)","volume":"6","author":"Tasian","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"26","key":"10.1016\/j.jcyt.2023.10.007_bib0018","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcyt.2023.10.007_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/0008-5472.CAN-18-1834","article-title":"Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors","volume":"79","author":"Lee","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jcyt.2023.10.007_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/icb.2016.128","article-title":"CAR T-cell therapy of solid tumors","volume":"95","author":"Yong","year":"2017","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcyt.2023.10.007_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"issue":"23","key":"10.1016\/j.jcyt.2023.10.007_bib0022","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J Cell Sci"},{"issue":"11","key":"10.1016\/j.jcyt.2023.10.007_bib0023","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-017-2045-4","article-title":"CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target","volume":"66","author":"Holzinger","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jcyt.2023.10.007_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0000000000000064","article-title":"CTLA-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice","volume":"38","author":"Mahvi","year":"2015","journal-title":"J Immunother"},{"issue":"14","key":"10.1016\/j.jcyt.2023.10.007_bib0025","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0026","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.jcyt.2023.10.007_bib0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther"},{"issue":"NOV","key":"10.1016\/j.jcyt.2023.10.007_bib0028","first-page":"1","article-title":"Effective targeting of TAG72+peritoneal ovarian tumors via regional delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcyt.2023.10.007_bib0029","doi-asserted-by":"crossref","first-page":"13545","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.jcyt.2023.10.007_bib0037","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2023.10.007_bib0031","first-page":"106","article-title":"Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models","volume":"8","author":"Han","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"15","key":"10.1016\/j.jcyt.2023.10.007_bib0032","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2023.10.007_bib0033","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"issue":"23","key":"10.1016\/j.jcyt.2023.10.007_bib0034","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jcyt.2023.10.007_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jcyt.2023.10.007_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"26","key":"10.1016\/j.jcyt.2023.10.007_bib0030","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"261","key":"10.1016\/j.jcyt.2023.10.007_bib0038","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.jcyt.2023.10.007_bib0039","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"March","key":"10.1016\/j.jcyt.2023.10.007_bib0040","first-page":"1","article-title":"Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects","volume":"13","author":"Qian","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2023.10.007_bib0041","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejso.2015.05.018","article-title":"Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review","volume":"41","author":"Van Oudheusden","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2023.10.007_bib0042","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","article-title":"EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss","volume":"20","author":"Sampson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jcyt.2023.10.007_bib0043","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for cancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jcyt.2023.10.007_bib0044","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jcyt.2023.10.007_bib0045","first-page":"105","article-title":"Defense mechanisms of the peritoneal cavity","volume":"7","author":"Broche","year":"2001","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"10.1016\/j.jcyt.2023.10.007_bib0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"van Baal","year":"2017","journal-title":"Tissue Cell"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923010794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923010794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:50:59Z","timestamp":1761443459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923010794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1465324923010794"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.10.007","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}